HIV Vaccine Progress
Andrew J. McMichael, Ph.D.
University of Oxford

• Lessons from the Rotavirus Vaccine: An Overview of the Issues
  F. Marc LaForce, M.D.
  Basic Support for Institutionalizing Child Survival (BASICS II)

• Lessons from the Rotavirus Vaccine: Ethical Considerations
  Christine Grady, R.N., Ph.D.
  National Institutes of Health

• A New Generation of Challenges for International Research Ethics
  James V. Lavery, M.D.
  National Institutes of Health

• Post-exposure DNA Vaccination Protects Mice Against Rabies Virus
  D. Lodmell and L. Ewalt
  Rocky Mountain Laboratories, NIAID, Hamilton, MT

• CD4 T Cells Transferred from VP6-immunized or Naïve Mice Were the Only Lymphocytes Needed to Resolve Rotavirus Shedding in Chronically Infected Rag-2 Mice
  R.L. Ward, M.M. McNeal, J.A. Flint, J.L. VanCott, and A.H-C. Choi
  Children's Hospital Medical Center, Cincinnati, OH

• Long-Term Effects of a Novel Liposomal gD Vaccine on Minimizing Intravaginal Herpes Simplex Virus Infection in Mice
  R. Masoud, L.H. Song, W. Ernst, G. Fuji, and J.P. Adler-Moore
  Cal Poly University, Pomona, CA, Molecular Express Inc., Los Angeles, CA

• Cytokine Response in Healthy Infants After Measles Vaccination
  I.G. Ovsyannikova, R.M. Jacobson, K.C. Reid, A.L. Oberg, L.K. Ledebuhr, G.G. Klee, and G.A. Poland
  Mayo Clinic and Foundation, Rochester, MN

• The Cytokine Response Following Hepatitis A Immunization
  M.S. Hayney, and J.M. Buck
  University of Wisconsin School of Pharmacy, Madison, WI

• Systemic and Mucosal (Local) Immune Response After Immunisation with New Type Low-Endotoxic LPS Vaccine Shigella sonnei
  P.G. Aparin, M.E. Golovina, V.I. Ershov, T.V. Gancho, V.I. Shmigol, L.I. Pavlova, R.P. Chuprynina, S.I. Yolkina, R.S. Rachmanov and V.L. L'vov
  National Research Center-Institute of Immunology, Moscow, Russia

• UBITh(tm) Synthetic Peptide Vaccine for FMDV in Swine
  A. Walfield, F. Shen, J. Yel, E. Kramer, M. Yeh, J. Lubroth, C.Y. Wang, F. Brown
  United Biomedical, Inc., Hauppauge, NY; USDA Plum Island Animal Disease Center, Greenport, NY

• Development of Live Attenuated Vaccines for Equine Infectious Anemia Virus (EIAV)
  F. Li, B. Puffer, K. Hennessy, C. Issel, and R. Montelaro
  University of Pittsburgh, Pittsburgh, PA; Intervet Inc., Merriam, KS; University of Kentucky, Lexington, KY

• The Development of Broad Spectrum Pulsed Light (BSPL) as the Critical Inactivation Step for the Manufacture of Vaccines
  W.H. Cover, J. Holloway, M. Landers and K. Salisbury
  Pure Pulse Technologies, Inc., San Diego, CA

• DNA Immunization with pgp3 Gene of Chlamydia trachomatis Inhibits the Spread of Chlamydial Infection from the Lower to the Upper Genital Tract in C3H/HeN Female Mice
  R. Cevenini, V. Sambri, M. Donati, K. Di Leo, M. Comanducci, and G. Ratti
  University of Bologna, Bologna, Italy; Chiron Vaccines, Siena, Italy

• HLA-DR3 Transgenic Mice have Impaired Lymphoproliferative Response to Measles Vaccine in vitro
  D.M. Phelan and G.A. Poland
  Mayo Clinic, Rochester, MN

• DOD-Wide Surveillance for Ill-Health Requiring Hospitalization Potentially Associated with Anthrax Immunization: 1998 Data
  P.A. Sato, T.C. Smith, R.J. Reed, L.Z. Wang
  Naval Health Research Center, San Diego, CA

• Assessing the Economic Value of Combination Vaccines
  E.C. Sewell, S.H. Jacobson, and B.G. Weniger
  Southern Illinois University, Edwardsville, IL; University of Illinois, Urbana, IL; CDC, Atlanta, GA

• Ineffectiveness of the Current Strategy to Prevent Hepatitis A in Travellers
  G. De Serres, B. Duval, R. Shadmani, N. Boulianne, G. Pohani, M. Naus, M. Douville Fradet, B.J. Ward, K.C. Kain
  Institut National de Santé Publique de Québec, Quebec; Laval University, Quebec; Ontario Ministry of Health and Long-Term Care, Toronto; Ministère de la Santé et des Services Sociaux de Québec, Quebec; Montreal General Hospital, Montreal; University of Toronto, Toronto

• Efficacy, Immunogenicity and Safety of the Malaria Vaccine RTS, S/SBAS02: An Overview
  N. Tornieporth, K. Bojang, L. Vigneron, M. Pinder, P. Milligan, O. Ofori-Anyinam, T. Doherty, M. Delchambre, K.E. Kester, D.G. Heppner, K. McAdam, B.M. Greenwood, A.V.S. Hill, and J. Cohen
  GlaxoSmithKline Biologicals, Rixensart, Belgium

• Yellow Fever (YF) 17D Virus as a Live Vector for Novel Chimeric Vaccines (ChimeriVax[TM]): Preclinical and Clinical Experience
  T.P. Monath, J. Arroyo, K. Pugachev, K. McCarthy, P. Bedford, and F. Guirakhoo
  Acambis Inc., Cambridge, MA

• Cross-Clade Conservation of HIV-1 CTL Epitopes in the Aidsvax® and Aventis CP205[TM] Vaccines
  N.K. Shah, M.J.B. Gonzales, A. Bosma, K.H. Mayer, and A.S. De Groot
  Brown University, Providence, RI; Memorial Hospital of Rhode Island, Pawtucket, RI

• Passive Immunity to Rotavirus as an Alternative to Direct Oral Vaccine J. Pacyna, G.P. Davidson, S.J. Terry, K. Siwek, E.S. Robertson, and R.B. Johnson
  NorthField Laboratories Pty Ltd., South Australlia; WCH, South Australia

• The Significance of Immunological Mimicry for the Development of New Vaccination Strategies
  Robert S. Fujinami, Ph.D.
  University of Utah School of Medicine

• Auto-Immunity Resulting from Bystander Immunological Effects
  Ethan M. Shevach, M.D.
  National Institute of Allergy and Infectious Diseases

• Integrated Approaches to Assess and Limit the Risk of Auto-Immune Adverse Effects
  Paul-Henri Lambert, M.D.
  University of Geneva

• Potential Vaccination Approaches to Prevent or Treat Auto-Immune Diseases
  David C. Wraith, Ph.D.
  University of Bristol

Symposium 3: Vaccines Against Malignancies and Chronic Diseases

• A Vaccine for Ulcers and Gastric Cancer: A Rationale for an H. pylori Vaccines
  Julie Parsonnet, M.D.
  Stanford University School of Medicine

• Vaccines Against Atherosclerosis
  Carl R. Alving, M.D.
  Walter Reed Army Institute of Research

• Attenuated Herpes Simplex Virus Vaccine Strain Expressing IL-12 in the Therapy of Gliomas
  Richard J. Whitley, M.D.
  University of Alabama at Birmingham School of Medicine

• Update on Dendritic Cell Vaccines
  Jacques Banchereau, Ph.D.
  Baylor Institute for Immunology Research

• Incidence and Clinical Presentation of a New Oculo-Respiratory Syndrome Associated and Influenza Vaccine
  N Boulianne, G. De Serres, B. Duval, R. Shadmani, and L. Rochette
  Institut National de Santé Publique de Québec, Quebec; Laval University, Quebec

• The Incidence of Oculo-Respiratory Syndrome (ORS) in Health Care Workers Following Influenza Vaccination
  D. Skowronski, D. MacDonald, E. Husain, J. Macnabb, E. Galanis, A. King, R. Parker and P. Daly
  BC Centre For Disease Control; BC Children's Hospital; Division of Immunization, Health Canada; Simon Fraser Health Region; Vancouver Richmond Health Region

• Investigation of an Ocular-Respiratory Syndrome Associated with Influenza Immunization, Canada, 2000
  E. Galanis, A. King, L. Palkonyay, C. Dubuc and the Oculo-Respiratory Working Group
  Division of Immunization, Health Canada; Field Epidemiology Training Program, Health Canada; Vaccines Division, Health Canada

• Characterization of Endogenous Avian Leukosis Viruses in a Chick Fibroblast Substrate Used in the Production of Measles and Mumps Vaccine
  J.A. Johnson and W. Heneine
  Centers for Disease Control and Prevention, Atlanta, GA

• Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Children and Adolescents with Moderate to Severe Asthma
  G. Redding, R.E. Walker, C. Hessel, F.S. Virant, G.H. Ayars, G. Bensch, J. Cordova, S. Holmes and P.M. Mendelman
  University of Washington School of Medicine, Seattle, WA; Aviron, Mountain View, CA; Northwest Allergy and Asthma Center, Seattle, WA; Allergy and Asthma Associates, Kirkland, WA; George Bensch, M.D., Inc., Stockton, CA

• Reactogenicity and Passage into the Brains of Enterotoxins and cpg-Oligonucleotides Administered Intranasally to Mice
  P. Bourguignon, M. Bisteau, S. Veenstra, P. Hermand, V. Hendrickx, M. Friede, Y. Lobet and M. Francotte
  GlaxoSmithKline, Rixensart, Belgium

• Down Modulation of Host Inflammatory Responses by RanC/d After Adenoviral Gene Therapy
  P.M.C. Wong, X. Huang, J. Arnott, and S-W. Chung
  Temple University School of Medicine, Philadelphia, PA

• A Novel Adjuvant Formulation Containing a Block Copolymer with Reverse Gelation Characteristics Elicits Long Lasting igG Antibody Responses After a Single Injection in Mice
  C. Coeshott, J. Blonder, E. Verderber, K. Harrington and G.J. Rosenthal
  RxKinetix Inc., Louisville, CO

• Incorporation of CD154 Into SIVgag VLP Results in Reduced in vivo Immunogenicity
  L. Giavedoni, S. Frey, M. Velasquillo, L. Parodi, and V. Hodara
  Southwest Foundation for Biomedical Research, and Southwest Regional Primate Research Center, San Antonio, TX

• Improved Efficacy of a Herpes Simplex Virus gD Vaccine Following Incorporation of Viral Epitope and Adjuvant in Liposomes
  L.H. Song, W. Ernst, G. Fuji and J.P. Adler-Moore
  Cal Poly University, Pomona, CA; Molecular Express Inc., Los Angeles, CA

• Clinical Trials of Group B Streptococcal Conjugate Vaccines: Effects of Alum Adjuvant and Booster Doses on Immunogenicity
  L.C. Paoletti, D.L. Kasper, D. Molrine, D. Ambrosino, and C.J. Baker
  Brigham and Women's Hospital; Harvard Medical School, Boston, MA; Baylor College of Medicine, Houston, TX

• Epidermal Powder Immunization of Influenza Vaccine with Cholera Toxin Induces Mucosal Immune Responses and Protection
  C. Erickson, R. Endres, L. Payne, and D. Chen
  PowderJect Vaccines, Inc., Madison, WI

• A Nasal Proteosome Influenza Vaccine Using a Baculovirus Hemagglutinin induces Improved Mucosal and Systemic Immunity
  D.H. Jones, F. Allard, S. Tran, M. Plante, J. Gauthier, K. Torossian, G. White, G.H. Lowell and D.S. Burt
  Intellivax International Inc., Ville St.-Laurent, Canada

• Phase I Evaluation of an Intranasal Proteosome-Influenza Vaccine in Healthy Adults
  J. Treanor, D. Burt, G. Lowell, and L. Fries
  University of Rochester, Rochester, NY; Intellivax International Inc., Ville St.-Laurent, Québec; Intellivax Inc., Baltimore, MD

• An Inactivated Whole-Virus Influenza Vaccine Given Intranasally Induced Protective Levels of Serum Antibodies in Humans
  H.H. Samdal, A.H. Berstad, F. Oftung, J. Holst, H. Bakke, I.L. Haugen, G.E. Korsvold, A-C. Kristoffersen, G. Krogh, K. Nord, and B. Haneberg
  National Institute of Public Health, Olso, Norway, Haukeland University Hospital, Bergen, Norway; University of Oslo, Norway

• Supra-Molecular Biovector[TM] and NonToxic E.Coli LTK63 Mutant for Intra-Nasal Immunisation with Meningococcal C Conjugated Vaccine
  D. Betbeder, B.C. Baudner, O. Balland, M.M. Giuliani, J. Petre, R. Rapp\uoli, G. Del Giudice and P. Von Hoegen
  Biovector Therapeutics, Labège, France; Chiron SpA, Siena, Italy

• Bordetella Pertussis May Act as Adjuvant as well as Inhibitor of Immune Responses to Nasal Vaccines
  A. Haugan, N. Wold, P.X.T. Dao, H. Bakke, I.L. Haugen, L. Janakova, A.K.H. Berstad, J. Holst, and B. Haneberg
  National Institute of Public Health, Oslo, Norway; Haukeland University Hospital, Bergen, Norway; University of Oslo, Norway

• A Phase 1C Study of a DNA Hepatitis B Vaccine in Healthy Patients Nonresponsive to Licensed Hepatitis B Vaccines: Preliminary Results
  G.A. Poland, S. Rottinghaus, R.M. Jacobson, and M. Roy
  Mayo Clinic, Rochester, MN; Powderject Vaccines, Madison, WI

• Antibody Responses to Bovine Parainfluenza Virus Type 3 (PIV3) Vaccination and Human PIV3 Infection in Young Infants

  M.S. Lee, D.P. Greenberg, S. Yeh, R. Yogev, K.S. Reisinger, J.I. Ward, M.M. Blatter, I. Cho, M.J. August, W. Chen, H.B. Mehta, K.L. Coelingh and P.M. Mendelman
  Aviron, Mountain view, CA; Children's Hospital of Pittsburgh, PA; UCLA Center for Vaccine Research, Torrence, CA; Children's Memorial Hospital, Chicago, IL; Primary Physicians Research, Pittsburgh, PA

• Safety and Immunogenicity of a 4-Dose Short Interval Oral, Inactivated Whole Cell Campylobacter Vaccine Co-administered with Modified Escherichia Coli Heat-labile (LT_R192G) Adjuvant iin Volunteers
  D.R. Tribble, S. Baqar, F. Trespalacios, J.W. Sanders, R. Walker, J.D. Clements, and D.A. Scott
  Naval Medical Research Center, Bethesda, MD; U.S. Army Medical Research Institute of Infectious Disease, Frederick, MD; Antex Biologics Inc., Gaithersburg, MD; Tulane University School of Medicine, New Orleans, LA

• Antibody Persistence, PRP-Specific Immune Memory & Booster Responses to DTPa/Hib Vaccine in Children Primed with a New Combination Vaccine DTPa-HBV-IPV/Hib at 2, 4, and 6 months of age
  T. Nolan, A. Altmann, G. Hogg, M. Skeljo, and L. Schuerman
  Royal Children's Hospital; University of Melbourne, Australia; GlaxoSmithKline, Australia & Belgium

• VaxGen's Global Strategy to Develop and Evaluate an HIV Vaccine, AIDSVAX[TM]
  W. Heyward, J. Curd, P. Berman, and D. Francis
  VaxGen, Inc., Brisbane, CA

• Phase III Efficacy Evaluation of AIDSVAX[TM]B/E HIV Vaccine in Bangkok, Thailand -- An Update
  K. Choopanya, S. Migasena, S. Vanichseni, P. Pitisuttithum, D. Kitayaporn, P. Yodane, K. Hiranrus, J. Tappero, and W. Heyward
  The Bangkok Vaccine Evaluation Group, Thailand; VaxGen, Inc., Brisbane, CA

• Global Epidemiology of Meningococcal Disease
  Bradley A. Perkins, M.D.
  Centers for Disease Control and Prevention

• The United Kingdom Experience with Meningococcal Disease
  David M. Salisbury, M.B.
  Department of Health, United Kingdom

• Vaccine Candidates for Group B Neisseria Meningitidis
  Rino Rappuoli, Ph.D.
  Chiron Vaccines

• Population-Based Incidence Rates of Invasive Pneumococcal Infection in Children in 7 Centers Across Canada, 1994-1998
  G. Bjornson, D. Scheifele, S. Halperin
  Members of the CPS/LCDC Immunization Monitoring Program, Active(IMPACT), Ottawa, ON, Canada.

• Estimates of Rotovirus Associated Diarrhea (RAD) Hospitalizations in Quebec Children From 1985 to 1998
  B.Duval, R.P. Buigues, L. Rochette, N. Boulianne, M.Douville-Fradet, P. Déry, G.De Serres
  Institute National de Santé publique du Québec, Québec, Canada; Unité de recherche en santé publique, Québec, Canada; Minstére de la Santé et des Services sociaux, Québec, Canada; Centre hospitalier Universitaire de Québec, Canada; Contributed equally

• Risk Factors for Vaccine Failures in Children Vaccinated with Acellular and Whole-cell Pertusis in Senegal
  K. Lacombe, S. Pinchinat, A. Yam, K. Simondon, F. Simondon
  Epidemiology and Prevention Unit, IRD Montpellier, France and Dakar, Senegal

• Social Harms Evaluation in the First Phase III HIV Vaccine Efficacy Trial
  L. Stoll and J. Jermano
  VaxGen, Inc, Brisbane, CA

• ELISPOT Assays for Evaluation of Antigen Specific Responses in HIV-1 Vaccinated Individuals
  M. Bailey, E. Kuta, E. Turk, L. Galley, M. Scoles, R. El Habib, P. Caudrelier, D. Schwartz, G. Ferrari, D. Birx, and J.H. Cox
  U.S. Military HIV Research Program, Rockville, MD; Aventis Pasteur, Marcy L'Etoile, France; Aventis Pasteur, Lyon, France; Johns Hopkins University, Baltimore, MD; Duke University Medical Center, Durham, NC

• Immunogenicity of Five Doses of Inactivated Mycobacterium vaccae Vaccine in HIV+ Subjects
  J.M. Vuola, M. Ristola, A. J”rviluoma, B.F. Cole, C.F. von Reyn
  National Public Health Institute, Helsinki, Finland; Helsinki University Central Hospital, Helsinki, Finland; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

• An Update on the Phase I Human Clinical Trial of an Epstein-Barr Virus Vaccine
  J. Bharadwaj, T. Ngyuen, G. Lawrence, S.L. Elliott, A. Suhrbier, and D.J. Moss
  Co-operative Research Center for Vaccine Technology, Queensland Institute of Medical Research, Brisbane, Australia

• Influenza Vaccination and Stroke in the Elderly -- A Community-based Observational Study in Korea
  B. Chun, W. Kim, M. Kim, H. Jeong, E. Kim, S. Park
  Konyang University Medical College, Nonsan, Korea; Korea University Medical College, Seoul, Korea

• The Meaning of the Strain Peculiarities of the Influenza Viruses for the Production Vaccines and Diagnostics
  I. Bezbrozh, G. Skripchenko, T. Rybakova
  Mechnikov Virology & Epidemiology Research Institute, Odessa, Ukraine

• The Mechanism of the Therapeutic Effect of the Commercial Inactivated Virion Vaccine Against Herpes Simplex Viruses 1 and 2 at Ophtalmoherpes and Genital Herpes
  I. Barinsky, E. Mordvinzeva
  D.I. Ivanovsky Institute of Virology RAMN; "Vitafarma" commercial firm, Russia

• Linear B-cell Epitopes of Human Respiratory Syncytial Virus Fusion Protein Indentified by Sera from Adults and Children
  R. Al-Torki, S. Jiang, P.E. Kofoed, P.Aaby, and M.W. Steward
  London School of Hygiene & Tropical Medicine, London, UK; Projecto de Saude de Bandim, Bissau, Guniea Bissau

• The Panton-Valentine Leucocidin (PVL) of Staphylococcus aureus Seems to be Correlated with Recurrent Furnunculosis in Humans but not with Inflammatory Diseases in Cattle
  O. Nolte, H.E. Weiss, H. Weiss, H.K. Geiss, H. Haag, H.G. Sonntag
  Hygiene Institute, Heidelberg, Germany

• Detection of Two Novel Antigenic Proteins in Leishmania Major
  M.R. Mohammady, M. Zeinali, A. Kariminia, and S.K. Ardenstani
  Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; Pasture Institute, Tehran

• Rapid Determination of Candidate HLA B*07 -- Restricted CTL Epitopes from the West Nile Virus NY99 Genome
  A.S. De Groot, C. Saint-Aubin, J. Rayner, W. Martin
  Brown University, Providence, RI; EpiVax, Inc., Providence, RI

• Characterization of Potential Vaccine Proteins of Mycobacterium paratuberculosis
  J. Mullerad, Y. Fishman, A. Hovav, I. Michal, R.G. Barletta, H. Bercovier
  Hebrew University, Jerusalem, Israel; University of Nebraska, Lincoln, NE

• Meningococcal group A Conjugates: Preclinical Studies
  A. Bartoloni, F. Norelli, G. Averani, A. Giannozzi, F. Di Pisa, E. Gallo, A. Martini, R. Paffetti, S. Berti, R. Rossi, A. Bardotti, S. Ricci, V. Carinci, S. D'Ascenzi and P. Costantino
  Chiron Vaccines, Siena, Italy

• DNA-mediated Immunization Methods with Human Cytomegalovirus (HCMV) Glycoprotein B (gB) for the Induction of Neutralizing Antibodies to HCMV in BALB/c Mice
  Y. Kwon, E. Park, S. Jeon, C. Park, E. Hwang, and C. Cha
  Seoul National University College of Medicine, Seoul, Korea

• Stable High Level Expression of Foreign Antigens from the Chromosome of Salmonella typhimurium Vaccine Strains
  T.D. Terry and M.P. Jennings
  University of Queensland, St Lucia, Queensland, Australia

• Evaluation of a Salmonella Pathogenicity Island-2 (SPI-2) Mutant of Salmonella typhi as a Vaccine Vector in Mice
  T. Bellaby, R. Stratford, N. McKelvie, S.M. Chattfield, F.R. Brennan and S.A. Khan
  Microscience Ltd., Berkshire, UK

• Characterization of Protective Immune Response Elicited by Alphavirus Replicons Expressing the Herpes Simplex Virus Type 2 (HSV-2) Glycoprotein H (gH)-Glycoprotein L (gL) Complex
  D. Long, R. Natuk, J. Kowalski, J. Strasser, S. Gangolli, E. Mishkin, D. Bernstein, and T. Zamb
  Viral Vaccine Research, Wyeth-Lederle Vaccines, Pearl River, NY; Immunology Research, Wyeth-Lederle Vaccines, Pearl River, NY; CHMC, Cincinnati, OH

• Effects of Conjugation Chemistry on Immunological Reactivity and Epitopes Expressed in Type III Group B Streptococcal Polysaccharide
  C.H. Lee, N. Concepcion, G. Arakere, and C.E. Frasch
  DBPAP, OVRR, CBER, FDA, Bethesda, MD

• The Use of Complex Surface Antigens of Salmonella, Escherichia, Proteus and Pseudomonas in Indirect Hemagglutination Assay
  L.V. Parkhomenko, S.I. Bidnenko, M.I. Grutman
  Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine

• Development of Complex Surface Antigens of Salmonella, Echerichia, Proteus and Pseudomonas
  V.N. Parkhomenko, M.I. Grutman, L.V. Parkhomenko, S.I. Andrianov, A.M. Shcherbinska
  Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine

• The Defense of Immune Sera to Complex Surface Antigens of Escherichia, Salmonella, Pseudomonas and Proteus Under Experimental Infection
  M.I. Grutman, L.V. Parkhomenko, V.N. Parkhomenko
  Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine

• A Standard Nomenclature for Vaccine Abbreviation
  B.G. Weniger
  National Immunization Program, CDC, Atlanta, GA

• The Joint Vaccine Acquisition Program for Biodefense Vaccines
  V. Peierson, L. Van de Verg, D. Steele, D. Danley
  Joint Vaccine Acquisition Program, Fort Detrick, MD

• Immunization with DNA Construct of a Peptide Mimeotope Induces a Cross-Reactive anti-Carbohydrate Antibody which Binds to HIV-1 Envelope Glycoprotein and Inhibits the Adhesion of Dendritic Cells to an Env Transfected Cell Line
  B. Monzavi-Karbassi, S. Shamloo, P.Luo, G. Cunto-Amesty, D.B. Weiner, T. Kieber-Emmons
  University of Pennsylvania, Philadelphia, PA

• Peptidomimics Selected from Phage Display Libraries Induced Neutralizing Antibody Response Against Japanese Encephalitis Virus
  S. Wu, C. Lin
  National Tsing Hua University, Hsinchu, Taiwan

• Immune Response to Oral Administered Autovaccines
  A. Bindewald, O. Nolte, H.E. Weiss, H. Weiss, H.G. Sonntag
  Hygiene Institute, Heidelberg, Germany

• Directed Molecular Evolution of Vaccine Antigens
  S. Bass, E. Karrer, A. Goel, R. Lyons, et al
  Maxygen Inc., Redwood City, CA; University of New Mexico, Albuquerque, NM

• The HIV-1 Vpu Protein and Generation of CD8+ T Cell Responses in Mice
  B.P. Nayak and A.M. Jabbar
  Emory University, Atlanta, GA

• Enhanced Immune Responses Elicited by DNA Vaccination with HIV gp120-C3d Fusion Constructs
  T.D. Green, Y. Xu, D.C. Montefiori, H.L. Robinson, and T.M.Ross
  East Carolina University, Greenville, NC; Emory University, Atlanta, GA; Duke University, Durham, NC

• Epidermal Powder Immunization with HIV gp120 Induces both Humoral and Cellular Immune Responses
  C. Zuleger, J. Osorio, d. Chen, L. Payne
  PowderJect Vaccines, Madison, WI

• The Role of T Cells in Varicella-Zoster Virus (VZV) Pathogenesis
  C. Ku, E. Butcher, and A. Arvin
  Stanford University, Stanford, CA

• Evolution of Envelope-Specific Antibody Responses Associated with the Development of Enduring Broadly Protective Immunity in Monkeys Inoculated with Attenuated SIV
  J.L. Rowles, K.S. Cole, M. Murphey-Corb, and R.C. Montelaro
  University of Pittsburgh School of Medicine, Pittsburgh, PA

• A Conjugated Papillomavirus-Like Particle Based Vaccine Generates High Titer Autoantibodies to TNF-aand Protects Against Arthritis Induction in a Mouse Model
  B. Chackerian, D.R. Lowy, and J.T. Schiller
  National Cancer Institute, Bethesda, MD

• The Expression and Role of the Murine Chemokine, I-TAC in Virus Infection
  H.H.R. Hamilton, S. Mahalingam, I.A. Ramshaw, S. Ramsay, S.A. Thomson
  The John Curtain School of Medical Research, The Australian National University, Canberra, ACT, Australia

• The Effect of Influenza Immunization on CYP3A4 Activity
  M.S. Harvey, J.M. Buck
  University of Wisconsin School of Pharmacy, Madison, WI

• The Association of TAPi and TAP2 Polymorphisms and Antibody Response to Live Measles Vaccine Virus
  N. Dhiman, I.G. Ovsyannikova, N. Pinsky, R.A. Vierkant, R.M. Jacobson, G.A. Poland
  Mayo Clinic and Foundation, Rochester, MN

• Comparison of Adjuvant Effects Elicited by Calcium Phosphate Nanoparticles Versus Alum
  Q. He, K. McCurn, T. Morcol, S.J.D. Bell
  BioSante Pharmaceuticals, Smyrna, GA

• Polyester Microparticles as a Vaccine Delivery System for Brucellosis
  C. Gamazo, M. Murillo, M.J. Grilló, J. Reñé, C.M. Martin, M. Barberán, M.M. Goñi, J.M. Blasco, J.M. Irache
  University of Navarra, Pamplona-Spain; Animal Health Unit, Zaragoza-Spain

• Induction of CD4 and CD8 T Cell Responses Using Antigen Encapsulated in Gelatin-Chondroitin Sulfate Microspheres
  D. Levin, E. Ivzada and R. Azhari
  Ort Braude College, Karmiel, Israel

• Different RSV and Quillaja saponin Formulation Induce Murine Peritoneal Cells to Express Different Proinflammatory Cytokine Profiles
  F. Hu, M. Chen, I. Abusugra, F. Monaco and B. Morein
  Swedish University of Agricultural Sciences, Uppsala, Sweden; Karolinska Institute, Stockholm, Sweden; Istituto Zooprofilattico Sperimentale Dell' Abruzzo e Del Molise 'G. Caporale', Teramo, Italy

• Decreased Non-typeable Haemophilus influenzae (NTHi) Infection Following P6 Liposomal Vaccination of Weaning Rats
  N. Said, W. Ernst, S. Yegiyants, L. Song, G. Fujii, and J.P. Adler-Moore
  Cal Poly, Pomona, CA; Molecular Express Inc., Los Angeles, CA

• Mucosal Administration of Totally Synthetic Lipopeptides without Adjuvant Induced Systemic Immune Reponses
  L. BenMohamed, Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe
  Cedars-Sinai Medical Center, Los Angeles, CA; Pasteur Institute, Paris, France; Institut de Biologie and Institute Pasteur de Lille, France

• The New Synthetic Compounds OM-294-MP and OM-294-DP Induce Cellular and Humoral Responses in 2 Murine Vaccine Models
  G. Corradin, D. River, O. Martin, G. Davies, J. Bauer
  University of Lausanne, Epalinges, Switzerland; University of Orléans, Orléans, France; 3OM PHARMA, Meyrin/Geneva, Switzerland

• The New Adjuvant OM-174 Induces Migration and Maturation of Dendritic Cells in Vivo In the Mouse
  B. Pajak, V. Garze, G. Davies, M. Moser, C. Chiavaroli
  Université Lidre de Bruxelles, Gosselies, Belgium; 2OM PHARMA, Meyrin/Geneva, Switzerland

• Immunosteroid Treatment of Aged Mice at Vaccination Increases Antibody Responses, and Elicits a Th1/Th2 Profile Resembling that of Young Animals
  Enioutina, R.J. Rigg, R.A. Daynes
  University of Utah, Salt Lake City, UT; Hollis-Eden Pharmaeuticals, San Diego, CA

• An Adjuvant-Antigen Model for Plant-based Mucosal Vaccine Production
  F. Medina-Bolivar, R. Wright, D. Sentz, T. Wilkins, W. Petri, Jr., and C. Cramer
  Virginia Tech; University of Virginia

• Influenza Virosomes are an Efficient Delivery System for RSV F Antigen Humoral and Cell-Mediated Immunity
  M.G. Cusi*, R. Zurbriggen, P. Correale, M. Valassina, P.E. Valensin, R. Glück
  University of Siena, Siena, Italy; Swiss Serum and Vaccine Institute Berne, Berne, Switzerland

Symposium 5: New Approaches to Vaccine Development

• Use of Novel Mass Spectrometry Technology in Vaccine Development
  Gregory A. Poland, M.D.
  Mayo Clinic and Foundation

• Use of Microchip Array and Gene Expression Technology in Vaccine Development
  Marcel A. Behr, M.D.
  McGill University

• Use of Transgenic Animal for Vaccine Development
  Harry M. Meade, Ph.D.
  Genzyme Transgenics

• Progress in the Use of Plants as Vaccine Production Delivery Systems
  Carol O. Tacket, M.D.
  University of Maryland School of Medicine

• Immunization of HPV+ Patients with High-Grade Anal Dysplasia Using a Microsphere Encapsulated DNA Vaccine (ZYC101) Results in HPV Specific Immune Responses
  M. Matijevic, B. Klencke, J. Palefsky, M.L. Hedley, and R.G. Urban
  ZYCOS Inc., Lexington, MA; University of California San Francisco Cancer Center, San Francisco, CA

• Therapeutic Vaccination Against Alzheimer's Disease
  K. Ugen, C. Dickey, M.N. Gordon, and D. Morgan
  Dept. of Med. Micro. and Immunol. and Dept. of Pharmacology, University of South Florida, Tampa, FL

• Restoration of a Functional Anti-HIV CD8 Immune Response in HLA-A2 HIV-Infected Patients Treated with a gag/pol env/rev DNA Vaccine
  J.D. Boyer, G. Silvestri, I.S. Gourley, C. Kang, M. Kamoun, R. Ginsberg, R.R. MacGregor and D. Weiner
  University of Pennsylvania; Hospital of the University of Pennsylvania, PA; Wyeth Lederle Vaccines, Pearl River, NY

• Preclinical Study of Dendritic Cells Pulsed with Alpha-galactosylceramide and Tumor-specific Peptide as Anti-cancer Vaccine
  M. Kataoka, K. Lyerly, and Y. Deng
  Eastern Virginia Medical School, Norfolk, VA; Duke University Medical School, Durham, NC

• Safety and Immunogenicity of a Transcutaneously Administered Prototype Traveler's Diarrhea Vaccine Consisting of Heat-Labile Toxin (LT) and CS6 Colonization Factor of Enterotoxigenic Escherichia coli (ETEC)
  F. Guereña, D.N. Taylor, E.R. Hall, D. Scott, M.K. Wolf, F.J. Cassels, Z.J. Roberts, C.R. Alving, G.M. Glenn
  WRAIR, Silver Spring, MD; Iomai Corp., Washington, D.C.; NMRC, Silver Spring, MD

• Epidermal Powder Immunization with Conventional Protein Vaccines
  L.G. Payne and D. Chen
  PowderJect Vaccines Inc., Madison, WI

• Macroflux® Skin Patch Technology: A Practical Intracutaneous Vaccination System
  J.A. Matriano, M. Cormier, J. Johnson, W.A. Young, M. Buttery, K. Nyam, and P.E. Daddona
  ALZA Corporation, Mountain View, CA

• Transdermal Hepatitis B Vaccine Delivery Through Thermally Created Micropores in Human Subjects
  A.M. Smith, J.A. Eppstein, T.J. Woods, M.S. McRae, D.W. Allen, and M.R. Hatch
  Altea Genomics Inc., Atlanta, GA

• Vaccines for Smallpox and Poxviruses
  James W. LeDuc, Ph.D.
  Centers for Disease Control and Prevention

• Vaccines for Lassa and Ebola Infections
  Joseph B. McCormick, M.D.
  Aventis Pasteur

• Progress on Vaccines for Brucellosis
  Colonel David L. Hoover, M.D.
  Walter Reed Army Institute of Research

• Update on Vaccines Against Anthrax
  Colonel Arthur M. Friedlander, M.D.
  U.S. Army Medical Research Institute of Infectious Diseases

• Current Research into Vaccines Against Plague
  Lieutenant Colonel Gerry P. Andrews, Ph.D.
  U.S. Army Medical Research Institute of Infectious Diseases

• Adventitious Agent Testing
  Philip R. Krause, M.D.
  U.S. Food and Drug Administration

• Update on Preservatives and Excipients
  William W. Egan, Ph.D.
  U.S. Food and Drug Administration

• Neurovirulence Testing
  Kathryn M. Carbone, M.D.
  U.S. Food and Drug Administration

• BSE-Implicated Components in the Preparation of Vaccines: An Update
  David M. Asher, M.D.
  U.S. Food and Drug Administration